Maura Campbell
President & CEO, OBIO®

Maura Campbell
President & CEO, OBIO®
Dr. Maura Campbell is the President and CEO of the Ontario Bioscience Innovation Organization (OBIO®), a not-for-profit, membership-based organization dedicated to advancing health technology innovation and commercialization. Dr. Campbell has more than 30 years of experience in all key areas of biotech, including private and public companies, universities and research institutes, and government-funded public sector research organizations.
With expertise in technology transfer and commercialization of intellectual property, Dr. Campbell has held various roles in senior management, most recently as the Vice-President of Intellectual Property and Contracts for Turnstone Biologics, which recently went public on the NASDAQ. She played a significant role in the company’s seed and Series A, B, C, and D financing, as well as the execution of two large pharma-licensing deals with AbbVie Inc. and Takeda Pharmaceuticals International Co. raising over $450 million (U.S.) for Turnstone. Previously, Dr. Campbell served as Director, Intellectual Property at VBI Vaccines. Among the various roles she held in her career are Senior Research Program Manager, and Manager of Technology Transfer & Commercialization at the Ottawa Hospital Research Institute, Director of Intellectual Property for PainCeptor Pharma Corporation, and Manager of Technology Transfer at the Institute for Robotics and Intelligent Systems National Centre of Excellence. Dr. Campbell has also served as an IP consultant to a number of Canadian start-ups including Neurochem, Conjuchem, Aonix, AMRIC and Sussex Research Labs.